Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.66 |
| ▸ | HPGD | P15428 | 6/20 | 0.66 |
| ▸ | GAA | P10253 | 4/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.66 |
| ▸ | GLA | P06280 | 1/20 | 0.66 |
| ▸ | CASP1 | P29466 | 1/20 | 0.66 |
| ▸ | CASP7 | P55210 | 1/20 | 0.66 |
| ▸ | ATM | Q13315 | 1/20 | 0.66 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29892849 | 1.00 | MAPT (0.66) | MAPTKDM4EALDH1A1HPGDGAA | |
| Hydrochloric Acid SCHEMBL6987193 | 0.98 | MAPT (0.64) | MAPTKDM4EALDH1A1HPGDGAA | |
| SCHEMBL1457756 | 0.85 | KDM4E (0.61) | MAPTKDM4EALDH1A1HPGDGAA | |
| Hydrochloric Acid SCHEMBL4418745 | 0.84 | MAPT (0.59) | MAPTKDM4EALDH1A1HPGDGAA | |
| SCHEMBL14012582 | 0.82 | CES2 (0.59) | MAPTKDM4EALDH1A1HPGDGAA | |
| SCHEMBL29375113 | 0.82 | KDM4E (0.72) | MAPTKDM4EALDH1A1HPGDGAA | |
| SCHEMBL192100 | 0.82 | KDM4E (0.72) | MAPTKDM4EALDH1A1HPGDGAA | |
| SCHEMBL29664708 | 0.82 | CES2 (0.59) | MAPTKDM4EALDH1A1HPGDGAA | |
| SCHEMBL383936 | 0.82 | CES2 (0.59) | MAPTKDM4EALDH1A1HPGDGAA | |
| SCHEMBL5596417 | 0.82 | HDAC1 (0.49) | MAPTKDM4EALDH1A1HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 356 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856179-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| EP-4737444-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | Gilead Sciences, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-2026087635-A1 | DIHYDRO BENZOXAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| US-12612412-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| US-12410146-B2 | Processes and intermediates for preparing MCL1 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250215013-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | IMPACT THERAPEUTICS (SHANGHAI), INC. (CN) | 2025-07-03 | — | — | US | disclosed |
| EP-4536363-A1 | SULFAMIDE DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | Nikang Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| CN-119790053-A | Sulfonamide derivatives as cyclin dependent kinase 2 inhibitors | 霖康疗法公司 | 2025-04-08 | — | — | CN | disclosed |
| WO-2003068230-A1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | PHARMACIA CORPORATION (US) | 2003-08-21 | — | — | WO | disclosed |
| EP-0853077-B1 | Process for producing alkyl 3-amino-4-substituted benzoates | SANKIO CHEMICAL CO LTD (JP) | 2003-04-16 | — | — | EP | disclosed |
| US-6479531-B1 | Gastrin and cholecystokinin receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 2002-11-12 | — | — | US | disclosed |
| EP-1178969-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2002-02-13 | — | — | EP | disclosed |
| EP-1175155-A1 | METHOD FOR REDUCING A SUSCEPTIBILITY TO TUMOR FORMATION INDUCED BY 3-DEOXYGLUCOSONE AND PRECURSORS THEREOF | FOX CHASE CANCER CENTER (US) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000062626-A1 | METHOD FOR REDUCING A SUSCEPTIBILITY TO TUMOR FORMATION INDUCED BY 3-DEOXYGLUCOSONE AND PRECURSORS THEREOF | FOX CHASE CANCER CENTER (US) | 2000-10-26 | — | — | WO | disclosed |
| WO-2000027823-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2000-05-18 | — | — | WO | disclosed |
| US-5514676-A | TO INHIBIT THE FORMATION OF ADVANCED GLYCOSLYATION PRODUCTS BY THE NONENZYMATIC CROSSLINKING OF PROTEINS WITH REDUCING SUGARS, USED IN FOOD PRESERVATION AND TO PREVENT PROTEIN AGING IN COLLAGEN OR LENSES IN THE EYE PRESERVATION | THE ROCKEFELLER UNIVERSITY (US) | 1996-05-07 | — | — | US | disclosed |
| EP-0543884-A1 | BENZANILIDE DERIVATIVES AND THEIR USE AS ANTI-ATHEROSCLEROTIC AGENTS | RHONE-POULENC RORER LIMITED (GB) | 1993-06-02 | — | — | EP | disclosed |
| WO-1992003408-A1 | BENZANILIDE DERIVATIVES AND THEIR USE AS ANTI-ANTHEROSCLEROTIC AGENTS | RHONE-POULENC RORER LIMITED (GB) | 1992-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410146-B2 | Processes and intermediates for preparing MCL1 inhibitors | MCL1, BAK1, BCL3 | MAPT 3023/4885KDM4E 1483/4885ALDH1A1 2336/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | MAPT 3782/4885KDM4E 3565/4885ALDH1A1 587/4885 |
| US-20250215013-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | PARP1, PARP2, PARP3 | MAPT 3973/4885KDM4E 1608/4885ALDH1A1 464/4885 |
| US-12612412-B2 | Antiviral heterocyclic compounds | ZC3HAV1, NHERF1, HM13 | MAPT 4663/4885KDM4E 342/4885ALDH1A1 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.